FI88360B - Foerfarande foer framstaellning av tumoerlaekemedel - Google Patents
Foerfarande foer framstaellning av tumoerlaekemedel Download PDFInfo
- Publication number
- FI88360B FI88360B FI853389A FI853389A FI88360B FI 88360 B FI88360 B FI 88360B FI 853389 A FI853389 A FI 853389A FI 853389 A FI853389 A FI 853389A FI 88360 B FI88360 B FI 88360B
- Authority
- FI
- Finland
- Prior art keywords
- mak
- cells
- mel
- antigens
- tumor
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 22
- 108091007433 antigens Proteins 0.000 claims abstract description 22
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 12
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 7
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 101100182914 Caenorhabditis elegans mak-1 gene Proteins 0.000 claims 4
- 210000002950 fibroblast Anatomy 0.000 claims 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- 210000005260 human cell Anatomy 0.000 abstract description 2
- 229960005486 vaccine Drugs 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000013049 sediment Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 3
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Window Of Vehicle (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Claims (3)
1. Förfarande för framställning av ett terapeutiskt medel för behandling av en tumörsjukdom, k ä n n e -5 tecknat därav, att humana tumörceller, som bär an-tigenerna 1 - 17 (Ag 1 - Ag 17) med molekylvikterna 33 kD ± 3 (Ag 1), 134 kD ± 3 (Ag 2), 80 kD ± 3 (Ag 3), 55 kD ± 3 (Ag 4), 60 kD ± 3 (Ag 5), 54 kD ± 3 (Ag 6), 260 kD ± 3 10 (Ag 7), obestämbara för Ag 8 och Ag 9, 143 kD ± 3 och 119 kD ± 3 (Ag 10), 178 kD (Ag 11), obe-stämbar för Ag 12, 34 kD ± 3 (Ag 13), 195 kD ± 3 (Ag 14), 44 kD ± 7 (Ag 15), obestämbar för Ag 16 och 130 ± 3 (Ag 17) (MAK 1 - MAK 17), varvid Ag 1 - Ag 17 rea-15 gerar med de monoklonala antlkropparna 1-17 (MAK 1 - MAK 17) och dessa antlkroppar besltter den i tabellen an-givna reaktionsmodellen 13 l δ 360 Antikropparnas MAK 1 - MAK 17 reaktivitet med in vitro-celler Testade celler
5 Lungtumör- cellinjer 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 CaLu—1 + + + + + -r + — + — E-14 -f — + + -*- + + -r + + — — — “ — -f
10 B 109/4 ++ -+ ___ - — - — — A 549 +++ +____ Oat 75 + + - + - + + + - + -- - + + --*- SHP — 77 + + — + +-r+ — + — Chago +
15 Bro-Ca-Hoff ++--+ - - +-- Bukspotts- körteltumör- cellinjer PaTuII + + - - + - - - + ± Pa Tu III +-+ +- -
20 MIA-Pa-Ca 2 - - - - - - - Pane-1 ++-+-++- ... Gynekologiska : tumörcellinjer ,';V 25 Bewo +- + + + + + - -- + + - + * ·' HeLa ++ +- + + -- - - - - + + - + : Pa-1 + + + + - + -- + - - - - - - + "V Melanom- cellinjer
30 Mel-ULF ++-+-++-± - + - + - + + . . Mel-RPMI + + - + — + + — + — — — + — + Mel-51-2 + + - + __-_± _ _ _ _ _ _ + _ Mel-21-C-48 + + - + + - + -+ + - + + - + + ’· '· obesläktade *:**: 25 tumörcell- linjer : ZR-75-1 + + - - + + - - +__ MCF-7 + + - +--- - - - - - - • a Mamma-Ca-12 + - - + + + Calon-Ca-Ax + - - - (forts..) 14 8 8 360 (forts.) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Colon-Wi + + -- -- ---- ___
5 HT-1080 + + - Leiomyosarkom + + Kypernephroin TUW IMP. 32 +-- -- --- ---- Paji + ----- _ ---
10 Daudi + ----- - --- 1788 + ----- 6666/1 +--_ --- Immunozytom +--+- -- Normala lymfoida celler Lymfocyter - ± - - - + Monocyter + + -- -- -- - _ _ _ _ _ + Granulocyter ++--+---- - - - - - - ± Erytrocyter ---------
20 Benmärg ++--+---- - - - - - + Normala humana fibroblaster LL-29 ++ -- --- -- ___ - 25 Hu-Fi-Br 32 + + + -- -- --- ------ Hu-Fi-Br 43 ++ -- ---- -- -- Hu-Fi-3r 47++------ -- Hu-Fi-Br 16 +++--- -- Hu-Fi-Mel-1 +++------- -- --
30 Hu-Fi-Mag-13 ++ _______ ___ __ Djurceller Vero _+_______ _ _ _ _ + Vinthund BHK ------+-- - ----- ; 35 Rättfibro- • blaster _________ Musfibro- blaster _________ _ _ _ _ _ 15 88363 + = signifikant positiv reaktion vid indirekt fluorecens-test, radioimmunobestämning och cytofluorometrisk bestäm-ning ± = svagt positiv reaktion med en del av de testade popu-5 lationerna * - - ingen signifikant reaktion torkas eller stabiliseras genom behandling med al-dehyd, varefter neuraminidas eventuellt tillsätts.
2. Förfarande enligt patentkravet 1, k ä n n e -10 tecknat därav, att man med nägon av antikropparna MAK 1 - MAK 17, som riktar sig mot antigenen Ag 1 - Ag 17, varvid antigenerna 1 - 17 (Ag 1 - Ag 17) har molekylvik-terna 33 kD
± 3 (Ag 1), 134 kD ± 3 (Ag 2), 80 kD ± 3 (Ag 3), 55 kD ± 3 15 (Ag 4), 60 kD ± 3 (Ag 5), 54 kD ± 3 (Ag 6), 260 kD + 3 (Ag 7), obestämbara för Ag 8 och Ag 9, 143 kD + 3 och 119 kD ± 3 (Ag 10), 178 kD (Ag 11), obe-stämbar för Ag 12, 34 kD ± 3 (Ag 13), 195 kD ± 3 (Ag 14), 44 kD ± 7 (Ag 15), obestämbar för Ag 16 och 20 130 ± 3 (Ag 17), och antikropparna MAK 1 - MAK 17 besitter den i krav 1, i tabell 1 angivna reaktionsmodellen, isole-rar en antigen ur humana tumörceller, varefter neuramini-das eventuellt tillsätts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843432714 DE3432714A1 (de) | 1984-09-06 | 1984-09-06 | Tumortherapeutikum und verfahren zu seiner herstellung |
| DE3432714 | 1984-09-06 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI853389A0 FI853389A0 (fi) | 1985-09-04 |
| FI853389L FI853389L (fi) | 1986-03-07 |
| FI88360B true FI88360B (fi) | 1993-01-29 |
| FI88360C FI88360C (sv) | 1993-05-10 |
Family
ID=6244749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI853389A FI88360C (sv) | 1984-09-06 | 1985-09-04 | Förfarande för framställning av tumörläkemedel |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0173951B1 (sv) |
| JP (1) | JPS6168427A (sv) |
| AT (1) | ATE64531T1 (sv) |
| CA (1) | CA1277600C (sv) |
| DE (2) | DE3432714A1 (sv) |
| DK (1) | DK172253B1 (sv) |
| ES (1) | ES8704082A1 (sv) |
| FI (1) | FI88360C (sv) |
| GR (1) | GR852149B (sv) |
| IE (1) | IE58638B1 (sv) |
| IL (1) | IL76289A (sv) |
| PT (1) | PT81093B (sv) |
| ZA (1) | ZA856807B (sv) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3806565A1 (de) * | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen |
| AT398900B (de) * | 1991-02-12 | 1995-02-27 | Pekar Rudolf Dr | Vakzine für eine immuntherapie |
| US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| CA2147499C (en) * | 1992-11-05 | 2010-10-19 | Ron S. Israeli | Prostate-specific membrane antigen |
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| DE69635801T2 (de) | 1995-02-24 | 2006-11-02 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
| DE19506483A1 (de) * | 1995-02-24 | 1996-08-29 | Jens Dr Dr Atzpodien | Lyophilisat-Vakzine |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| JP5355839B2 (ja) | 2001-10-23 | 2013-11-27 | ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． | Ｐｓｍａ抗体およびタンパク質マルチマー |
| CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152410A (en) * | 1975-09-03 | 1979-05-01 | Eisai Co., Ltd. | Diagnosis reagent for neoplasm and method for diagnosis of neoplasm |
| DE2643215A1 (de) * | 1976-09-25 | 1978-04-06 | Bayer Ag | Cancerostatisch wirksame praeparationen aus tumorzellen und ein verfahren zu ihrer herstellung |
| ZA776822B (en) * | 1976-11-24 | 1979-06-27 | D Mccollester | Vaccine and method for immunotherapy of neoplastic disease |
| DE2918927A1 (de) * | 1979-05-10 | 1980-11-20 | Hans Prof Dr Limburg | Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung |
| US4446122A (en) * | 1979-12-28 | 1984-05-01 | Research Corporation | Purified human prostate antigen |
| US4468457A (en) * | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| DE3329184A1 (de) * | 1983-08-12 | 1985-02-21 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene |
| DE3416774A1 (de) * | 1984-05-07 | 1985-11-14 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper, verfahren zu ihrer herstellung sowie ihre verwendung |
-
1984
- 1984-09-06 DE DE19843432714 patent/DE3432714A1/de not_active Withdrawn
-
1985
- 1985-08-27 AT AT85110757T patent/ATE64531T1/de not_active IP Right Cessation
- 1985-08-27 EP EP85110757A patent/EP0173951B1/de not_active Expired - Lifetime
- 1985-08-27 DE DE8585110757T patent/DE3583265D1/de not_active Expired - Fee Related
- 1985-09-03 DK DK402485A patent/DK172253B1/da not_active IP Right Cessation
- 1985-09-04 GR GR852149A patent/GR852149B/el unknown
- 1985-09-04 ES ES546701A patent/ES8704082A1/es not_active Expired
- 1985-09-04 FI FI853389A patent/FI88360C/sv not_active IP Right Cessation
- 1985-09-04 IL IL76289A patent/IL76289A/xx not_active IP Right Cessation
- 1985-09-05 CA CA000490026A patent/CA1277600C/en not_active Expired - Lifetime
- 1985-09-05 JP JP60195000A patent/JPS6168427A/ja active Pending
- 1985-09-05 ZA ZA856807A patent/ZA856807B/xx unknown
- 1985-09-05 PT PT81093A patent/PT81093B/pt not_active IP Right Cessation
- 1985-09-05 IE IE219185A patent/IE58638B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI853389A0 (fi) | 1985-09-04 |
| ES546701A0 (es) | 1987-03-16 |
| IL76289A0 (en) | 1986-01-31 |
| ES8704082A1 (es) | 1987-03-16 |
| PT81093B (pt) | 1988-07-01 |
| GR852149B (sv) | 1986-01-03 |
| DK402485A (da) | 1986-03-07 |
| DE3583265D1 (de) | 1991-07-25 |
| JPS6168427A (ja) | 1986-04-08 |
| EP0173951B1 (de) | 1991-06-19 |
| PT81093A (de) | 1985-10-01 |
| FI88360C (sv) | 1993-05-10 |
| FI853389L (fi) | 1986-03-07 |
| IE58638B1 (en) | 1993-10-20 |
| CA1277600C (en) | 1990-12-11 |
| IL76289A (en) | 1992-01-15 |
| EP0173951A3 (en) | 1988-06-08 |
| ZA856807B (en) | 1986-04-30 |
| DE3432714A1 (de) | 1986-04-24 |
| EP0173951A2 (de) | 1986-03-12 |
| DK172253B1 (da) | 1998-02-09 |
| ATE64531T1 (de) | 1991-07-15 |
| DK402485D0 (da) | 1985-09-03 |
| IE852191L (en) | 1986-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1194794A (en) | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom | |
| Deelder et al. | Schistosoma mansoni: demonstration of two circulating antigens in infected hamsters | |
| FI88360B (fi) | Foerfarande foer framstaellning av tumoerlaekemedel | |
| Ablin et al. | Tissue-and species-specific antigens of normal human prostatic tissue | |
| US4224404A (en) | Production of specific immune nucleic acids cell dialysates and antibodies | |
| Nowinski et al. | Characteristics of the structural components of the mouse mammary tumor virus: II. Viral proteins and antigens | |
| US4816253A (en) | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| Billing et al. | Human leukemia antigen. I. Production and characterization of antisera | |
| JPH01501939A (ja) | 免疫抑制ペプチドおよび使用法 | |
| JPS60500716A (ja) | ウイルス腫瘍遺伝子からの合成ポリペプチド | |
| US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| JPH06205671A (ja) | 形質転換細胞の抽出および培養ならびにそれらに対する抗体の製造 | |
| CN105175527A (zh) | 一种乳腺癌特异性的热休克蛋白复合物及其应用 | |
| Hollinshead et al. | Reactivity between herpesvirus type 2-related soluble cervical tumor cell membrane antigens and matched cancer and control sera | |
| US4758549A (en) | Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses | |
| Peacock et al. | Rapid fluorescent-antibody conjugation procedure | |
| Sarkar et al. | Identification of the structural proteins of the murine mammary tumor virus that are serologically related to the antigens of intracytoplasmic type-A particles | |
| Charney et al. | Demonstration, purification, and partial characterization of abnormal (HSL) antigens in stable human cell lines | |
| US5002878A (en) | Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses | |
| Hager et al. | Antibodies in normal rabbit serum that react with tissue-specific antigens on the plasma membranes of human adenocarcinoma cells | |
| US6294172B1 (en) | Monoclonal antibodies with specificity for membrane-associated antigens | |
| Sorg et al. | Immunological Properties of Amylose, Dextran and Polyvinylalcohol Conjugated with Polytyrosyl‐Peptides | |
| Shearer et al. | Cellular analysis of immunosuppression to synthetic polypeptide immunogens induced by a murine leukemia virus | |
| Wingen et al. | Evidence for developmental changes of type IV collagen in glomerular basement membrane | |
| Lee et al. | The use of antifibrin antibodies for the destruction of tumor cells: I. Localization of antifibrin antibodies in a methylcholanthrene-induced sarcoma in guinea pigs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed |
Owner name: BEHRINGWERKE AKTIENGESELLSCHAFT |